This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Xal-Ease on Patient Compliance With Xalatan (Xal-Ease)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Augusta University.
Recruitment status was:  Recruiting
Information provided by:
Augusta University Identifier:
First received: December 7, 2007
Last updated: August 7, 2008
Last verified: August 2008
The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN

Condition Intervention
Glaucoma Device: Xal-Ease device to be used with Xalatan eye drops

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops

Resource links provided by NLM:

Further study details as provided by Augusta University:

Primary Outcome Measures:
  • The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment. [ Time Frame: six months ]

Secondary Outcome Measures:
  • To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen [ Time Frame: six months ]
  • To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye. [ Time Frame: 6 months ]

Estimated Enrollment: 50
Study Start Date: February 2005
Estimated Study Completion Date: December 2009
Intervention Details:
    Device: Xal-Ease device to be used with Xalatan eye drops
    This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40 to 80 years old
  • Diagnosis warranting treatment with Xalatan eye drops.
  • ambulatory and well functioning

Exclusion Criteria:

  • non-ambulatory
  • less than 40 or greater than 80 years old
  • Not using Xalatan eye drops
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00573638

Contact: Christian D. Nilson, MD 706-721-1150
Contact: Sandra M. Johnson, MD 706-721-1150

United States, Georgia
Medical College of Georgia Health Inc Recruiting
Augusta, Georgia, United States, 30912
Sponsors and Collaborators
Augusta University
Principal Investigator: Christian D. Nilson, MD Augusta University
  More Information

Responsible Party: Michelle Christiano, Medical College of Georgia Identifier: NCT00573638     History of Changes
Other Study ID Numbers: 05-02-266
Guarantor or CPI # 002533552
Study First Received: December 7, 2007
Last Updated: August 7, 2008

Keywords provided by Augusta University:
eye drops
deliver aid
Patients could range anywhere from 40 to 80 years old
Patients must have diagnosis requiring treatment with Xalatan.
Patients will be male or female and from any racial/ethnic background.

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents
Antihypertensive Agents processed this record on August 18, 2017